|
業務類別
|
Biotechnology |
|
業務概覽
|
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform,PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsindeficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease. |
| 公司地址
| 7 Straits View No. 12-00, Marina One East Tower, Singapore, SGP, 018936 |
| 電話號碼
| +65 62363388 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.wavelifesciences.com |
| 員工數量
| 317 |
| Dr. Paul B. Bolno, M.B.A.,M.D. |
President, Chief Executive Officer and Director |
美元 655.50K |
26/02/2026 |
| Dr. Christopher Francis, PhD |
Senior Vice President, Corporate Development and Head of Emerging Areas |
美元 438.30K |
23/06/2025 |
| Mr. Kyle Moran, C.F.A. |
Chief Financial Officer and Principal Accounting Officer |
美元 497.20K |
26/02/2026 |
| Dr. Chandra Vargeese, PhD |
Chief Technology Officer and Head of Platform Discovery Sciences |
美元 487.54K |
23/06/2025 |
|
|
| Mr. Christian O. Henry |
Chairman of the Board |
26/02/2026 |
| Dr. Mark H.N. Corrigan, M.D. |
Independent Director |
26/02/2026 |
| Mr. Adrian Rawcliffe |
Independent Director |
26/02/2026 |
| Dr. Gregory L. Verdine, PhD |
Director |
26/02/2026 |
| Dr. Peter Kolchinsky, PhD |
Independent Director |
26/02/2026 |
| Ms. Heidi L. Wagner, J.D. |
Independent Director |
26/02/2026 |
| Dr. Paul B. Bolno, M.B.A.,M.D. |
President, Chief Executive Officer and Director |
26/02/2026 |
| Mr. Ken Takanashi |
Independent Director |
26/02/2026 |
| Ms. Aik Na Tan |
Independent Director |
26/02/2026 |
|
|
|
|
